InSilico Medicine (HKG:3696) said it has not made any concrete decision on a secondary listing at this stage and will make further announcements if there are any material developments, according to a Wednesday Hong Kong bourse filing.
Bloomberg reported earlier, citing people familiar with the matter, that the AI-driven drug discovery company was considering a secondary listing in Abu Dhabi, potentially becoming the first company from outside the Gulf to list shares on a regional exchange.
The report said InSilico Medicine had held preliminary discussions about a listing on the Abu Dhabi Securities Exchange as early as this year.